104 related articles for article (PubMed ID: 11750103)
41. Expression of SOCS1 and CXCL12 Proteins in Primary Breast Cancer Are Associated with Presence of Circulating Tumor Cells in Peripheral Blood.
Smolkova B; Mego M; Horvathova Kajabova V; Cierna Z; Danihel L; Sedlackova T; Minarik G; Zmetakova I; Krivulcik T; Gronesova P; Karaba M; Benca J; Pindak D; Mardiak J; Reuben JM; Fridrichova I
Transl Oncol; 2016 Jun; 9(3):184-90. PubMed ID: 27267835
[TBL] [Abstract][Full Text] [Related]
42. Myosin-IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia.
Wigton EJ; Thompson SB; Long RA; Jacobelli J
J Leukoc Biol; 2016 Jul; 100(1):143-53. PubMed ID: 26792819
[TBL] [Abstract][Full Text] [Related]
43. Cell adhesion manipulation through single cell assembly for characterization of initial cell-to-cell interaction.
Gou X; Wang R; Lam SS; Hou J; Leung AY; Sun D
Biomed Eng Online; 2015 Dec; 14():114. PubMed ID: 26652601
[TBL] [Abstract][Full Text] [Related]
44. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
Sison EA; Magoon D; Li L; Annesley CE; Romagnoli B; Douglas GJ; Tuffin G; Zimmermann J; Brown P
Oncotarget; 2015 Oct; 6(31):30902-18. PubMed ID: 26360610
[TBL] [Abstract][Full Text] [Related]
45. IQGAP1 promotes CXCR4 chemokine receptor function and trafficking via EEA-1+ endosomes.
Bamidele AO; Kremer KN; Hirsova P; Clift IC; Gores GJ; Billadeau DD; Hedin KE
J Cell Biol; 2015 Jul; 210(2):257-72. PubMed ID: 26195666
[TBL] [Abstract][Full Text] [Related]
46. CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target.
de Lourdes Perim A; Amarante MK; Guembarovski RL; de Oliveira CE; Watanabe MA
Cell Mol Life Sci; 2015 May; 72(9):1715-23. PubMed ID: 25572297
[TBL] [Abstract][Full Text] [Related]
47. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
[TBL] [Abstract][Full Text] [Related]
48. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo.
Li X; Guo H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2014 Oct; 4():6610. PubMed ID: 25312253
[TBL] [Abstract][Full Text] [Related]
49. Regulation of hematopoietic and leukemic stem cells by the immune system.
Riether C; Schürch CM; Ochsenbein AF
Cell Death Differ; 2015 Feb; 22(2):187-98. PubMed ID: 24992931
[TBL] [Abstract][Full Text] [Related]
50. Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology.
Patel B; Dey A; Castleton AZ; Schwab C; Samuel E; Sivakumaran J; Beaton B; Zareian N; Zhang CY; Rai L; Enver T; Moorman AV; Fielding AK
Blood; 2014 Jul; 124(1):96-105. PubMed ID: 24825861
[TBL] [Abstract][Full Text] [Related]
51. GSK-3β inhibition promotes early engraftment of ex vivo-expanded haematopoietic stem cells.
Dolnikov A; Xu N; Shen S; Song E; Holmes T; Klamer G; O'Brien TA
Cell Prolif; 2014 Apr; 47(2):113-23. PubMed ID: 24517125
[TBL] [Abstract][Full Text] [Related]
52. Advances in understanding the leukaemia microenvironment.
Tabe Y; Konopleva M
Br J Haematol; 2014 Mar; 164(6):767-78. PubMed ID: 24405087
[TBL] [Abstract][Full Text] [Related]
53. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis.
Cojoc M; Peitzsch C; Trautmann F; Polishchuk L; Telegeev GD; Dubrovska A
Onco Targets Ther; 2013 Sep; 6():1347-61. PubMed ID: 24124379
[TBL] [Abstract][Full Text] [Related]
54. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.
Sison EA; Rau RE; McIntyre E; Li L; Small D; Brown P
Br J Haematol; 2013 Mar; 160(6):785-97. PubMed ID: 23294096
[TBL] [Abstract][Full Text] [Related]
55. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.
Parameswaran R; Yu M; Lyu MA; Lim M; Rosenblum MG; Groffen J; Heisterkamp N
Leukemia; 2012 Aug; 26(8):1786-96. PubMed ID: 22373785
[TBL] [Abstract][Full Text] [Related]
56. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.
Chao MP; Tang C; Pachynski RK; Chin R; Majeti R; Weissman IL
Blood; 2011 Nov; 118(18):4890-901. PubMed ID: 21828138
[TBL] [Abstract][Full Text] [Related]
57. The bone marrow microenvironment and leukemia: biology and therapeutic targeting.
Sison EA; Brown P
Expert Rev Hematol; 2011 Jun; 4(3):271-83. PubMed ID: 21668393
[TBL] [Abstract][Full Text] [Related]
58. Cellular elements of the subarachnoid space promote ALL survival during chemotherapy.
Akers SM; Rellick SL; Fortney JE; Gibson LF
Leuk Res; 2011 Jun; 35(6):705-11. PubMed ID: 21269691
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.
Konopleva M; Tabe Y; Zeng Z; Andreeff M
Drug Resist Updat; 2009; 12(4-5):103-13. PubMed ID: 19632887
[TBL] [Abstract][Full Text] [Related]
60. Novel postremission strategies in adults with acute myeloid leukemia.
Lancet JE; Karp JE
Curr Opin Hematol; 2009 Mar; 16(2):105-11. PubMed ID: 19468272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
